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Abstract: AIMS The coronavirus disease 2019 (COVID-19) has spread rapidly around the globe, causing
significant morbidity and mortality. This study aims to describe electrocardiographic (ECG) characteris-
tics of COVID-19 patients and to identify ECG parameters that are associated with cardiac involvement.
METHODS AND RESULTS The study included patients who were hospitalized with COVID-19 diagnosis
and had cardiac biomarker assessments and simultaneous 12-lead surface ECGs. Sixty-three hospitalized
patients (median 53 [inter-quartile range, 43-65] years, 76.2% male) were enrolled, including patients
with (n = 23) and without (n = 40) cardiac injury. Patients with cardiac injury were older, had more
pre-existing co-morbidities, and had higher mortality than those without cardiac injury. They also had
prolonged QTc intervals and more T wave changes. Logistic regression model identified that the number
of abnormal T waves (odds ratio (OR), 2.36 [95% confidence interval (CI), 1.38-4.04], P = 0.002) and QTc
interval (OR, 1.31 [95% CI, 1.03-1.66], P = 0.027) were independent indicators for cardiac injury. The
combination model of these two parameters along with age could well discriminate cardiac injury (area
the under curve 0.881, P < 0.001) by receiver operating characteristic analysis. Cox regression model
identified that the presence of T wave changes was an independent predictor of mortality (hazard ratio,
3.57 [1.40, 9.11], P = 0.008) after adjustment for age. CONCLUSIONS In COVID-19 patients, presence
of cardiac injury at admission is associated with poor clinical outcomes. Repolarization abnormalities on
surface ECG such as abnormal T waves and prolonged QTc intervals are more common in patients with
cardiac involvement and can help in further risk stratification.
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Abstract
Aims The coronavirus disease 2019 (COVID-19) has spread rapidly around the globe, causing significant morbidity and mor-
tality. This study aims to describe electrocardiographic (ECG) characteristics of COVID-19 patients and to identify ECG param-
eters that are associated with cardiac involvement.
Methods and results The study included patients who were hospitalized with COVID-19 diagnosis and had cardiac biomarker
assessments and simultaneous 12-lead surface ECGs. Sixty-three hospitalized patients (median 53 [inter-quartile range, 43–65]
years, 76.2% male) were enrolled, including patients with (n = 23) and without (n = 40) cardiac injury. Patients with cardiac
injury were older, had more pre-existing co-morbidities, and had higher mortality than those without cardiac injury. They also
had prolonged QTc intervals and more T wave changes. Logistic regression model identified that the number of abnormal T
waves (odds ratio (OR), 2.36 [95% confidence interval (CI), 1.38–4.04], P = 0.002) and QTc interval (OR, 1.31 [95% CI, 1.03–
1.66], P = 0.027) were independent indicators for cardiac injury. The combination model of these two parameters along with
age could well discriminate cardiac injury (area the under curve 0.881, P < 0.001) by receiver operating characteristic analysis.
Cox regression model identified that the presence of T wave changes was an independent predictor of mortality (hazard ratio,
3.57 [1.40, 9.11], P = 0.008) after adjustment for age.
Conclusions In COVID-19 patients, presence of cardiac injury at admission is associated with poor clinical outcomes. Repo-
larization abnormalities on surface ECG such as abnormal T waves and prolonged QTc intervals are more common in patients
with cardiac involvement and can help in further risk stratification.
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Introduction
The coronavirus disease 2019 (COVID-19) pandemic has
caused millions of infectious cases and considerable
mortality.1 Many studies have described the clinical charac-
teristics of patients with COVID-19.2–7 Cardiac injury has
been observed as a common complication, ranging from
10% to 30% among hospitalized cases,3,4,8,9 exacerbating
severity and mortality of the disease. Monitoring of cardiac
involvement in patients with COVID-19 is of utmost impor-
tance to evaluate the progression of disease and its
prognosis.
SHORT COMMUNICAT ION
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Surface electrocardiographic (ECG) findings have not been
systematically reported in COVID-19, except for in some case
studies describing representative ECGs of special cases.10–12
The evaluation of cardiac involvement by measuring serum
cardiac biomarkers has often been reserved for high-risk indi-
viduals or suspected cases. An association between surface
ECG characteristics and cardiac injury, if confirmed, can be
of clinical relevance, because ECG can be used as a
non-invasive monitoring strategy to reflect a possible cardiac
involvement in patients with COVID-19. In the present study,
we aimed to describe ECG characteristics of COVID-19 pa-




This single-centre, observational study included laboratory
confirmed COVID-19 patients who were treated at the
Jinyintan Hopital in Wuhan, China, between 1 January 2020
and 27 February 2020. The cases who had no cardiac bio-
marker testing or surface ECG were excluded. This study com-
plied with the Declaration of Helsinki and was approved by
the Institutional Review Board of the Jinyintan Hospital. Writ-
ten informed consent was provided from all patients.
Clinical data collection
The clinical data and 12-lead surface ECG were simulta-
neously collected during the hospitalization (by J. T., W. H.,
and P. Z.). Serum cardiac biomarkers were collected including
high-sensitivity troponin I (hs-TnI), myohaemoglobin, and cre-
atinine kinase-myocardial band at the time of ECG recordings
for these patients. Cardiac injury was defined as at least one
elevated cardiac biomarker (above the 99th percentile upper
reference limit). The ECGs were evaluated by two experts
(F. D. and M. C.) who were blinded to the patient groups. Ab-
normal T wave was defined as T wave inversion (TWI), iso-
electric, or biphasic T wave. The degree of T wave
abnormality was determined as prominent TWI, mild TWI,
or isoelectric T wave. Treatment and outcome data were re-
corded during hospitalization (by N. H.). The clinical outcomes
were defined as hospital discharge or death.
Statistical analysis
Continuous variables were presented as median
(inter-quartile range [IQR]) values. Comparisons between
two groups were performed by Mann–Whitney U test or
Fisher’s exact test, as appropriate. Paired Student’s t-test
was used to compare paired samples between the two
groups. Spearman test was used for correlation analysis be-
tween hs-cTnI and number of abnormal T waves. Logistic re-
gression analysis with odds ratio (OR) and 95% confidence
intervals (CIs) was used to determine the independent factors
reflecting cardiac injury. Receiver operating characteristic
(ROC) with area the under curve (AUC) analyses were used
to assess the prediction value with optimal sensitivity and
specificity. Multivariable Cox regression with hazard ratio
(HR) and 95% CI was used to evaluate the predictors for
mortality.
Results
Patient characteristics and laboratory findings
The study included 63 patients (53 [IQR, 43–65] years, 15
[23.8%] female) including 23 patients (36.5%) with cardiac in-
jury and 40 patients (63.5%) without cardiac injury. The pa-
tient characteristics were presented in Table 1. Compared
with patients without cardiac injury, patients with cardiac in-
jury were older and more often had baseline co-morbidities
such as hypertension, coronary heart disease, arrhythmias,
and cancer. In addition to significantly elevated cardiac bio-
markers, patients with cardiac injury also showed higher leu-
kocytes count, aspartate transaminase, high-sensitivity
C-reaction protein, D-dimer, serum ferritin, and lactic dehy-
drogenase. Renal function, lipid, and interleukin 6 (IL6) were
comparable between two groups (Table 1).
Clinical course and outcomes
Table 2 shows the treatment, complications, and clinical out-
comes. Compared with patients without cardiac injury, pa-
tients with cardiac injury required more glucocorticoids and
non-invasive ventilation and showed more frequent
hypoproteinaemia and acute respiratory distress syndrome,
and more often progressed to severe condition. As a conse-
quence, the mortality rate was higher among patients with
vs. without cardiac injury (12 [52.2%] vs. 5 [12.5%],
P = 0.001).
Electrocardiographic characteristics
Most patients with COVID-19 showed abnormal ECG fea-
tures, such as sinus tachycardia (17.5%), abnormal T waves
(48.3%), and ST segment changes (7.9%) (Table 3). Compared
with patients without cardiac injury, patients with cardiac in-
jury showed prolonged QTc interval (452 [423, 479] vs. 428
[407.5, 439.5], P = 0.006), more abnormal T wave leads (2
[1, 2] vs. 0 [0, 1], P < 0.001), and more severe T wave
ECG characteristics in COVID-19 4409
ESC Heart Failure 2020; 7: 4408–4415
DOI: 10.1002/ehf2.12991
alterations (P = 0.002). In addition, sinus tachycardia (7
[30.4%] vs. 4 [10.0%], P = 0.041) and Q wave (4 [17.4%] vs.
1 [2.5%], P = 0.037) were more often observed among pa-
tients with vs. without cardiac injury. Figure 1A shows repre-
sentative ECGs from patients with and without cardiac injury.
Electrocardiographic and cardiac injury
We enrolled a logistic regression model to identify indicators
of cardiac injury among ECG features as well as routine labo-
ratory blood tests (Table 4). After adjustment for age,
Table 1 Baseline characteristics and laboratory findings of 63 patients with coronavirus disease 2019




(n = 23) P value
Female 15 (23.8) 9 (22.5) 6 (26.1) 0.750
Age, years 53 (43, 65) 48 (39, 62) 61 (49, 75) 0.007
Systolic pressure, mmHg 124 (115, 140) 125.5 (119, 141.5) 120 (110, 136) 0.123
Diastolic pressure, mmHg 77 (70, 85) 78.5 (70, 84) 72 (66, 87) 0.597
Signs and symptoms at admission, n (%)
Fever 56 (88.9) 34 (85) 22 (95.7) 0.199
Cough 47 (74.6) 28 (70) 19 (82.6) 0.272
Chest tightness 29 (46) 19 (47.5) 10 (43.5) 0.760
Palpitation 1 (1.6) 1 (2.5) 0 (0) 1.000
Dyspnoea 25 (39.7) 14 (35) 11 (47.8) 0.320
Fatigue 18 (28.6) 9 (22.5) 9 (39.1) 0.163
Sputum 18 (28.6) 11 (27.5) 7 (30.4) 0.805
Muscle ache 5 (7.9) 3 (7.5) 2 (8.7) 0.867
Diarrhoea 8 (12.7) 5 (12.5) 3 (13) 1.000
Chest pain 2 (3.2) 2 (5) 0 (0) 0.529
Headache 3 (4.8) 3 (7.5) 0 (0) 0.293
Sore throat 4 (6.3) 4 (10) 0 (0) 0.287
Hypertension 17 (27) 7 (17.5) 10 (43.5) 0.027
Diabetes 11 (17.5) 6 (15) 5 (21.7) 0.732
Coronary heart disease 4 (6.3) 0 (0) 4 (17.4) 0.015
Arrhythmias 5 (7.9) 1 (2.5) 4 (17.4) 0.055
COPD 4 (6.3) 2 (5) 2 (8.7) 0.566
Cancer 3 (4.8) 0 (0) 3 (13) 0.045
Laboratory findings at admission, median (IQR)
SpO2 (%) 95 (89, 98) 97 (94, 98) 92 (84, 95) 0.001
Leukocytes, /μL 6.36 (4.16, 9.83) 5.63 (3.44, 8.12) 8.69 (5.14, 11.26) 0.008
Erythrocytes, /μL 4.41 (4.02, 4.74) 4.44 (4.04, 4.92) 4.26 (3.92, 4.61) 0.558
Haemoglobin, g/dL 132 (122, 141) 131.5 (123, 141) 132 (118, 142) 0.869
Platelets, /μL 176 (133, 272) 187 (134.5, 278.5) 166 (132, 229) 0.617
Lymphocytes, /μL 0.84 (0.59, 1.25) 0.88 (0.56, 1.33) 0.83 (0.63, 1.08) 0.842
Creatine, μmol/L 71.9 (64, 84.6) 77.7 (66.3, 87) 68.7 (52.5, 84.2) 0.109
eGFR, ×mL/(min × 1.73 m
2
) 103.52 (86.37, 123.33) 101.79 (84.42, 121.87) 113.15 (86.51, 148.21) 0.226
Albumin, g/L 33.3 (29.2, 37.4) 35.75 (31.65, 38.9) 31.4 (28.6, 35.3) 0.036
Total bilirubin, μmol/L 13.05 (9.9, 17.3) 13.2 (10, 17) 12.9 (9.5, 18) 0.965
AST, U/L 40 (26, 49) 34.5 (25.5, 43.5) 45 (30, 55) 0.012
ALT, U/L 32.5 (23, 43) 32 (23, 43) 33 (20, 53) 0.748
Total cholesterol, mmol/L 3.88 (3.15, 4.63) 3.98 (3.18, 4.55) 3.73 (3.01, 4.68) 0.743
Triglyceride, mmol/L 1.17 (0.96, 1.76) 1.14 (0.96, 1.76) 1.21 (0.94, 1.86) 0.867
LDL-C, mmol/L 2.29 (1.75, 2.65) 2.36 (1.91, 2.68) 2.21 (1.51, 2.61) 0.173
HDL-C, mmol/L 0.98 (0.81, 1.17) 0.96 (0.82, 1.13) 1.13 (0.78, 1.26) 0.526
hs-CRP, mg/L 26.7 (7.35, 69.7) 17.1 (4, 71.5) 47.1 (21.9, 67.9) 0.027
PaO2, kPa 9.36 (7.81, 14.08) 9.12 (7.75, 13.57) 9.36 (8.24, 14.16) 0.605
D-dimer, μg/mL 0.79 (0.36, 2.97) 0.48 (0.26, 1.66) 2.11 (0.55, 22.47) 0.002
Serum ferritin, ng/mL 757.85 (420.33, 1280.95) 523.65 (300.83, 808.35) 1035.7 (787.29, 2000) 0.001
ESR, mm/h 41 (28, 53.7) 39.25 (27.65, 48.05) 48.2 (31, 66) 0.075
Interleukin 6, pg/mL 8.68 (6.65, 11.2) 8.68 (6.73, 11.92) 8.73 (6.32, 10.93) 0.706
hs-TnI, pg/mL 6.1 (2.6, 14.4) 3.55 (1.1, 8.75) 13.1 (5.7, 79) <0.001
Myohaemoglobin, ng/mL 71 (34.7, 139.7) 52.1 (30.8, 76.6) 147.65 (77.7, 230.1) <0.001
BNP, pg/mL 36.3 (12.6, 85) 27.4 (3, 50.9) 73.6 (32.1, 324.25) 0.007
Creatinine kinase, U/L 96 (67, 175) 80.5 (65.5, 133.5) 139 (67, 349) 0.074
CK-MB, U/L 15 (12, 19) 15 (11, 17) 18 (14, 26) 0.005
Lactic dehydrogenase, U/L 352 (236, 473) 276.5 (217, 417) 416 (327, 631) 0.001
ALT, alanine aminotransferase; AST, aspartate transaminase; BNP, B-type natriuretic peptide; CK-MB, creatinine kinase-myocardial band;
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; HDL-C,
high density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reaction protein; LDL-C, low density lipoprotein cholesterol
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baseline co-morbidities, leukocyte counts, albumin, and as-
partate transaminase, both number of abnormal T waves
(OR, 2.36 [95% CI, 1.38–4.04], P = 0.002) and QTc intervals
(OR, 1.31 [95% CI, 1.03–1.66], P = 0.027) were independent
predictors for cardiac injury. Spearman test validated positive
correlation between number of leads with abnormal T waves
and hs-cTnI levels among patients with COVID-19 (r = 0.66,
P < 0.0001), which suggests the extent of abnormal T waves
leads reflecting the severity of cardiac injury (Figure 1B). ROC
curve analysis confirmed that both QTc and number of leads
with abnormal T waves could discriminate cardiac injury with
AUC of 0.716 (P = 0.006) and 0.798 (P < 0.001), respectively
(Figure 1C, D). The discrimination reached 0.881 (AUC) as we
used a combined model of age, number of leads with abnor-
mal T waves, and QTc interval (P < 0.001), with a sensitivity
of 77.3% and specificity of 83.3% (Figure 1E).
Multivariate Cox regression analysis indicated that age and
cardiac injury were independent predictors of mortality in
patients with COVID-19. When we included age and ECG pa-
rameters into the Cox regression model, presence of T wave
changes was still an independent predictor (HR = 3.57 [1.40,
9.11], P = 0.008) for mortality when adjusted by age (Table 5).
Dynamic alterations of electrocardiogram
In order to investigate the dynamic alterations of ECG along
with the progression of cardiac injury among patients with
COVID-19, we enrolled a subgroup of eight patients who de-
veloped cardiac injury during hospitalization and had serial
ECG examinations from baseline to the time of cardiac injury.
Our results showed that QTc intervals and the number of
leads with abnormal T waves were significantly increased
(P = 0.001 and P = 0.001, respectively), along with elevation
of cardiac injury biomarkers hs-TnI and myohaemoglobin, in
parallel to the progression of cardiac involvement (Figure
Table 2 Treatment, complications, and clinical outcome of patients with coronavirus disease 2019
Characteristics Total (n = 63) Without cardiac injury (n = 40) With cardiac injury (n = 23) P value
Treatment
Antiviral drugs 57 (90.5) 35 (87.5) 22 (95.7) 0.402
Antibiotics 60 (95.2) 38 (95) 22 (95.7) 1.000
Glucocorticoids 33 (52.4) 17 (42.5) 16 (69.6) 0.040
Immunoglobulin therapy 14 (22.2) 8 (20) 6 (26.1) 0.579
Oxygen inhalation 37 (73.0) 27 (67.5) 19 (82.6) 0.197
Non-invasive ventilation 17 (27) 6 (15) 11 (47.8) 0.005
Invasive ventilation 1 (1.6) 0 (0) 1 (4.3) 0.365
Complications
ARDS 15 (23.8) 7 (17.5) 8 (34.8) 0.124
Acute kidney injury 2 (3.2) 1 (2.5) 1 (4.3) 1.000
Hypoproteinaemia 18 (28.6) 7 (17.5) 11 (47.8) 0.011
Anaemia 4 (6.3) 2 (5) 2 (8.7) 0.619
Hypoxaemia 23 (36.5) 12 (30) 11 (47.8) 0.160
Outcome
Critical condition 32 (50.8) 13 (32.5) 19 (82.6) <0.001
Death 17 (27) 5 (12.5) 12 (52.2) 0.001
Table 3 Electrocardiographic characteristics of patients with coronavirus disease 2019
Characteristics Total (n = 63) Without cardiac injury (n = 40) With cardiac injury (n = 23) P value
Heart rate, b.p.m. 80 (71, 89) 77 (68, 86.5) 85 (77, 101) 0.018
PR interval, ms 150 (139, 165) 155 (139, 164) 147 (139, 166) 0.597
QRS duration, ms 92 (86, 99) 92 (87, 100) 89 (84, 95) 0.155
QT interval, ms 372 (354, 402) 373 (355, 403) 369 (354, 402) 0.911
QTc, ms 432.5 (413, 452) 428 (407.5, 439.5) 452 (423, 479) 0.006
Sinus tachycardia 11 (17.5) 4 (10.0) 7 (30.4) 0.041
Branch bundle block 5 (7.9) 4 (10) 1 (4.3) 0.644
ST segment changes 5 (7.9) 3 (7.5) 2 (8.7) 1.000
Q wave 5 (7.9) 1 (2.5) 4 (17.4) 0.037
Abnormal T waves (≥1 lead) 29 (48.3) 11 (28.9) 18 (81.8) <0.001
Severity of abnormal T wave
a
0.002
Prominent T wave 9 (15) 4 (10.5) 5 (22.7)
Mild TWI 10 (16.7) 4 (10.5) 6 (27.3)
Isoelectric T wave 10 (16.7) 3 (7.9) 7 (31.8)
Normal 31 (51.7) 27 (71.1) 4 (18.2)
No. of abnormal T waves 0 (0, 2) 0 (0, 1) 2 (1, 2) <0.001
a
Abnormal T wave was defined as T wave inversion (TWI), isoelectric, or biphasic T wave.
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2A). In addition, after patients completely recovering, the ab-
normal T waves of some patients were able to return back to
normal as shown in one patient with comparable ECGs at ad-
mission and discharged from hospital (Figure 2B). These
Figure 1 T wave changes associated with cardiac injury among patients with coronavirus disease 2019 (COVID-19). (A) Representative electrocardio-
gram (ECG) from patients with (upper panel, female, 70 years old, QTc 459 ms) and without (lower panel, 30 years, QTc 423 ms) cardiac injury. (B)
Spearman correlation analysis between number of abnormal T waves and serum high-sensitivity troponin I (hs-TnI) concentrations. Receiver operating
characteristic (ROC) curve in discriminating cardiac injury by number of abnormal T waves (C), QTc interval (D), and combined model of age, number of
abnormal T waves and QTc interval with a sensitivity of 77.3% and specificity of 83.3% (E).
Table 4 Logistic regression to identify cardiac injury using electro-
cardiographic features and routine laboratory parameters
Variables OR (95% CI) P value
Age (per 10 years) 1.64 (1.09–2.47) 0.017
No. of abnormal T waves 2.36 (1.38–4.04) 0.002
QTc (per 10 ms) 1.31 (1.03–1.66) 0.027
Q wave — 0.059
Sinus tachycardia — 0.740
Hypertension — 0.275
Coronary heart disease — 0.199
Leukocytes — 0.349
Albumin — 0.859
Aspartate transaminase — 0.204
Table 5 Multivariable Cox regression prediction of mortality in pa-
tients with coronavirus disease 2019
Variables
Hazard ratio (95%
confidential interval) P value
Age + clinical variables
Age (per 10 years) 1.77 (1.27, 2.47) 0.001
Cardiac injury 8.77 (2.41, 31.95) 0.001
Hypertension — 0.537




Age + ECG parameters
Age (per 10 years) 1.86 (1.37, 2.53) <0.001
Abnormal T waves ≥ 2 3.57 (1.40, 9.11) 0.008
QTc ≥ 448 ms — 0.090
ST segment changes — 0.885
Bundle branch block — 0.924
Q wave — 0.407
Heart rate — 0.723
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results validated that ECG alterations in patients with
COVID-19 were associated with the presence of cardiac in-
jury, and there were dynamic changes during disease
progression.
Discussion
Cardiac injury associated with prognosis
Cardiac injury was commonly reported in patients with
COVID-19, with a prevalence ranging from 10% to 30% at
hospital admission.8,9 Patients with cardiac injury had a con-
siderably high mortality rate (more than 50%), compared
with the ~2.3% among the overall disease population.8,9,13
Our study has also revealed a similar mortality rate in patients
with cardiac injury (52.2%), much higher than the mortality
rate in patient without cardiac injury (12.5%). Our Cox regres-
sion analysis also demonstrated the independent role of car-
diac injury in predicting mortality. Therefore, it is of utmost
importance to detect cardiac involvement in patients with
COVID-19 and a 12-lead surface ECG can help for identifying
these patients. Other clinical conditions such as old age and
the presence of chronic obstructive pulmonary disease were
also reported to be associated with higher mortality in pa-
tients with COVID-19.9
Surface electrocardiogram and cardiac injury
Abnormal ECG features such as ST segment changes and
presence of Q wave and bundle branch block were observed
in a minority of cases in our cohort, which were also reported
by previous case series.10,14 In contrast, T wave changes were
common findings with a prevalence of 48.3% in the whole
study cohort. The number of leads with abnormal T waves
was significantly higher among patients with vs. without car-
diac injury, and this was also significantly correlated with se-
rum hs-cTnI levels. In addition, patients with cardiac injury
had longer QTc intervals, and none of these patients received
chloroquine or hydroxychloroquine therapy that might have
induced QT prolongation.15 We further demonstrated that T
wave changes along with QTc interval and age could be used
as a substantial predictor of cardiac injury with good discrim-
ination. Therefore, considering that cardiac biomarkers are
not routinely tested in clinical practice, ECG can be of clinical
importance in determining cardiac involvement in COVID-19
patients. As old age with presence of cardiovascular
co-morbidities may be a confounder for QTc and T wave
changes, the dynamic alterations of ECG from baseline to
Figure 2 Dynamic changes of electrocardiogram (ECG). (A) The ECG parameters and cardiac biomarker alterations from baseline to the time of cardiac
injury (compared by paired Student’s t-test). (B) Representative ECG from one patient (male, 65 years old) during cardiac injury (upper panel) and re-
covery state (lower panel).
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progressive disease are clinically more applicable for monitor-
ing cardiac involvement in patients with COVID-19.
Potential mechanism underlying cardiac injury
The mechanisms underlying cardiac injury caused by
SARS-CoV-2 remain unknown. A newly proposed theory has
focused on endothelial involvement causing microvascular
dysfunction across different organ systems.16 Our recent
study has revealed that cardiac pericytes (a perivascular cell
type that wrap around capillaries) have high expression of
angiotensin-converting enzyme 2 (ACE2), the putative viral
receptor and, therefore, may serve as the target cell of
SARS-CoV-2,17 which was later validated by an independent
study.18 Therefore, pericyte injury due to virus infection
may result in capillary endothelial dysfunction, thus inducing
microvascular dysfunction.17 The representative signature of
T wave alterations among COVID-19 patients with cardiac in-
jury was also previously demonstrated to be a predictor of
coronary microvascular dysfunction in patients with
non-obstructive disease.19
This study was a retrospective, observational study and in-
cluded only a limited number of cases. ECG findings from
larger multicentre cohorts are warranted to investigate the
role of ECG in predicting cardiac injury and prognosis in
COVID-19.
In summary, presence of cardiac injury in COVID-19 pa-
tients is associated with poor clinical outcome. ECG
repolarization abnormalities such as abnormal T waves and
prolonged QTc intervals are more common in patients with
cardiac involvement and can help in identifying these pa-
tients. Larger multicentre cohorts are warranted to investi-
gate the role of ECG findings in predicting cardiac injury in
COVID-19.
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